Skip to Main Content

Stephanie M. Roberts

Associate
stephanie.roberts@kattenlaw.com
New York Office
p+1.212.940.6674
Overview

Stephanie Roberts is an associate in the Intellectual Property practice.

Shown below is a selection of Stephanie’s engagements.

Experience
  • Representation of Mylan in an infringement dispute defending multiple patents for the brand name drug Evoclin®, a topical foam approved by the FDA for the treatment of acne; defendant Glenmark Pharmaceuticals alleged the filings were “sham litigation” to delay approval of a generic. Katten successfully persuaded the US District Court for the District of Delaware to dismiss the antitrust counterclaim.
  • Counsel for some of the world's largest pharmaceutical companies in several Hatch-Waxman litigations.
  • Litigation in the US District Court for the District of Delaware involving multiple patents associated with a pre-colonoscopy bowel preparation using sodium picosulfate, magnesium oxide and anhydrous citric acid.
  • Counsel for one of the world’s largest fresh-produce distributors in a plant patent litigation filed in the US District Court for the Southern District of Florida.
  • Litigation in the US District Court for the District of Delaware involving a method of use patent associated with the drug rivaroxaban.
  • Litigation in the US District Court for the District of Delaware involving multiple patents associated with the drug rotigotine for the treatment of early-stage idiopathic Parkinson’s disease and moderate-to-severe restless legs syndrome.
  • Litigation in the US District Court for the District of New Jersey involving multiple patents associated with methylnaltrexone bromide formulation for subcutaneous injection for the treatment of opioid-induced constipation.
  • Litigation in the US District Court for the District of Delaware involving multiple patents associated with the drug linaclotide for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
  • Litigation in the US District Court for the District of Delaware defending a patent for the brand name drug Olux-E®, a topical foam approved by the FDA for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
  • Litigation in the US District Court for the District of Delaware involving multiple patents associated with the drug vortioxetine hydrobromide for the treatment of major depressive disorder.
  • Litigation in the US District Court for the District of New Jersey involving multiple patents associated with the drug canagliflozin for the treatment of glycemic control in adults with type 2 diabetes mellitus.
  • Litigation in the US District Court for the Southern District of Florida involving a patent associated with the use of the drug levocetirizine dihydrochloride to treat symptoms associated with seasonal and perennial allergic rhinitis.
  • While at a prior firm:
    • Litigation in the US District Court for the District of New Jersey involving multiple patents associated with the drug aripiprazole for the treatment of schizophrenia, bipolar disorder, depression and autism spectrum disorders.
    • Litigation in the US District Court for the District of Delaware involving multiple patents associated with an injectable acetaminophen formulation.
    • Litigation in the US District Court for the District of New Jersey involving a patent associated with the nonsteroidal anti-inflammatory drug bromfenac ophthalmic solution (0.7%) for the treatment of postoperative inflammation and reduction of ocular pain in cataract patients.
Stephanie M. Roberts

Bar Admissions

  • New York
Katten Websites   Careers  |  Alumni  |  Mobile Site
Contact Us   Offices  |  Media Center  |  People  |  Email
Legal Notices   Disclaimer  |  Privacy Notice  |  Cookie Notice  |  United Kingdom Notices  | Accessibility 
© 2018 Katten Muchin Rosenman LLP